bioMérieux obtains CE-marking for LUMED™ APSS™, a
cutting-edge software solution to aid medical decision-making
in Antimicrobial Stewardship
Marcy l’Étoile, France, April 7th, 2025 – bioMérieux, a world leader in the field of in
vitro diagnostics, announces the CE marking of LUMED™ APSS™, an advanced
clinical decision support system (CDSS) designed to enhance antimicrobial
stewardship programs (ASP) and improve patient outcomes.

Antimicrobial resistance (AMR) poses a significant global health threat, with the World
Health Organization ranking it among the top public health threats worldwide1. Each
year, AMR is responsible for approximately 1.27 million deaths2. Health information
technologies – including clinical decision support systems – are crucial in combating this
issue. They enable faster and more accurate identification of pathogens and resistance
mechanisms, allowing healthcare providers to make data-driven decisions and select the
most effective treatments promptly.

LUMED™ APSS™ is a software solution designed for infectious disease (ID)
pharmacists and physicians as an aid to address the challenges of antimicrobial overuse
and misuse, which contribute to the rise of drug-resistant organisms. The system's multi-
step process helps ensure antimicrobial treatments are continuously evaluated and
adjusted based on the latest clinical data, promoting the de-escalation of unnecessary
treatments and the use of oral alternatives when appropriate.

The solution also includes support and training for medical teams to ensure a seamless
implementation of LUMED™ APSS™ and help them adopt best practices in antibiotic
therapy. It is tailored to meet the unique needs of Antimicrobial Stewardship (AMS)
committees in hospitals.

"bioMérieux is committed to advancing healthcare through innovative diagnostic
solutions. The introduction of LUMED™ APSS™ is a game-changer for antimicrobial
stewardship. Its ability to provide real-time alerts and prioritize patient reviews based on
local practice contexts is invaluable. This system not only supports optimal antimicrobial
prescribing but also helps improve patient safety and reduce healthcare costs3," stated
Dr Charles K. Cooper, Executive Vice President, Chief Medical Officer, bioMérieux.

The LUMED™ APSS™ clinical decision support system was developed by Lumed, a
Canada-based company acquired by bioMérieux in 2024. Additionally, an advanced
surveillance module, LUMED™ ZINC™ is available to help prevent infections in
hospitals. LUMED™ solutions complete bioMérieux’s portfolio dedicated to Antimicrobial
Stewardship (AMS – see below) and also strengthen its suite of digital solutions called
BIOMÉRIEUX VISION SUITE.

“Data-driven diagnostic support tools, such as LUMED™, go beyond the lab,
empowering healthcare professionals with real-time antimicrobial assessment for
informed therapy decisions, while helping hospitals optimize Antimicrobial Stewardship
programs ― driving improved patient, healthcare, and economic outcomes. LUMED™
APSS™ strengthens bioMérieux’s comprehensive portfolio of solutions to advance
Antimicrobial Stewardship and combat Antimicrobial Resistance, reinforcing our
commitment to preserve antibiotic efficacy both now and for future generations,” added
Jennifer Zinn, Executive Vice President, Clinical Operations, bioMérieux.
Already available in several countries, LUMED™ APSS™ will now be deployed
throughout Europe thanks to the CE-marking. An extended roll out worldwide is planned
in the coming years.

1
https://www.who.int/news-room/fact-sheets/detail/antimicrobial-resistance
2
Murray CJ. Global Burden of Bacterial Antimicrobial Resistance in 2019: A Systematic Analysis. The Lancet.
2022;399(10325):629-655. doi:https://doi.org/10.1016/S0140-6736(21)02724-0.
3
Nault V, Pepin J, Beaudoin M, Perron J, Moutquin JM, Valiquette L. Sustained impact of a computer-assisted
antimicrobial stewardship intervention on antimicrobial use and length of stay. J Antimicrob Chemother. 2017
Mar 1;72(3):933-940. doi: 10.1093/jac/dkw468. PMID: 27999034.



ABOUT BIOMÉRIEUX’S COMPLETE ANTIMICROBIAL STEWARDSHIP (AMS) SOLUTION
bioMérieux’s healthcare mission is to help sustain the use of antibiotic efficacy for generations to come.
To support hospitals, institutions, and laboratories with their AMS programs, bioMérieux has a complete
solution covering antibiotic therapy initiation, optimization, and discontinuation. This constantly evolving
offer provides timely, accurate results to adjust therapy, transforms data into actionable insights, and
integrates smoothly into any hospital with its flexible partnership approach. bioMérieux has more than 60
years of microbiology expertise with 75% of its R&D directed to research on antimicrobial resistance to
ensure the current offer evolves to meet customers’ AMS needs.

ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and
serves more than 160 countries with the support of a large network of distributors. In 2024, revenues
reached €4 billion, with over 93% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software, and services) which determine the
source of disease and contamination to improve patient health and ensure consumer safety. Its products
are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in
food, pharmaceutical and cosmetic products.
www.biomerieux.com.
bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP


CONTACTS
Investor Relations
Aymeric Fichet
Tel.: +33 (0)4 78 87 20 00
investor.relations@biomerieux.com

Media Relations
bioMérieux United States France
Romain Duchez Liza Deckelbaum (Seez) Laurence Heilbronn (Image 7)
Tel.: +33 (0)4 78 87 21 99 Tel.: 919.645.0782 Tel.: +33 (0)1 53 70 74 64
media@biomerieux.com lizad@seeztoday.com lheilbronn@image7.fr